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ABSTRACT
Currently used diagnostic criteria in different endemic (Balkan)
nephropathy (EN) centers involve different combinations of
parameters, various cut-off values and many of them are not in
agreement with proposed international guidelines. Leaders of
EN centers began to address these problems at scientiﬁc meet-
ings, and this paper is the outgrowth of those discussions. The
main aim is to provide recommendations for clinical work on
current knowledge and expertise. This document is developed
for use by general physicians, nephrologists, urologist, public
health experts and epidemiologist, and it is hoped that it will be
adopted by responsible institutions in countries harboring EN.
National medical providers should cover costs of screening
and diagnostic procedures and treatment of EN patients with
or without upper urothelial cancers.
INTRODUCTION
This paper represents updated recommendations developed
during the ‘International workshop on diagnostic criteria on
Endemic Nephropathy’ held in Brač, Croatia, in 2008. The ﬁnal
comments were made at a meeting organized in 2012 (Skopje,
Macedonia). The original aims of the workshop were to provide
recommendations for the screening, diagnosing and therapy of
patients with endemic (Balkan) nephropathy (EN) based on
current knowledge. Leading experts were invited to address
speciﬁc issues in the ﬁelds of public health, epidemiology, basic
science, nephrology, urology, pathology, oncology and radiology.
Data were presented and discussed in several expert sessions and
at the end all panelists met in the ﬁnal executive session to
prepare the consensus statement. PubMed was searched using
terms Balkan endemic nephropathy, aristolochic acid (AA) ne-
phropathy and urothelial cancers, and systematic literature
review was circulated with speciﬁc questions prepared in advance
to deﬁne the scope of the meeting. The Consensus statement is
intended to serve as the scientiﬁc document of the conferences. It
is developed for use by general physicians, nephrologists, urolo-
gist, public health experts and epidemiologist, and reﬂects the
current state of knowledge and will need to be modiﬁed accord-
ing to the development of new data and evidence.
It is hoped that the criteria proposed here will be adopted
in all countries harboring EN. Importantly, by using same di-
agnostic criteria and clinical guidelines, it will become feasible,
for the ﬁrst time, to compare results obtained in countries
where EN and associated upper urothelial cancers (UUC)
remain a major medical problem.
Endemic (Balkan) nephropathy
EN, a chronic tubulointerstitial nephropathy characterized
by an insidious onset and gradual progression to end-stage
renal disease (ESRD), was ﬁrst described 50 years ago and
remains an important medical, social and economic burden
for all countries harboring this devastating disease [1]. The
number of patients undergoing dialysis remains unchanged
[1–4]. However, a shift to older ages has been recorded among
newly diagnosed cases pointing to lower exposure. High preva-
lence of UUC is an important characteristic of EN [1, 4, 5].
A variety of environmental agents have been investigated
[1, 6–8]. The most widely studied ochratoxin A was rejected as
an important factor for EN/UUC by the EU Committee on Food
Safety [9]. Recent studies strongly suggest that AA is a major
risk factor for EN/UUC most likely ingested via home-baked
bread prepared from ﬂour contaminated by seeds of Aristolo-
chia clematitis [10–12]. Identiﬁed deoxyadenosine-aristolactam
(dA-AL) DNA adducts in the renal cortex of patients with
UUC and EN but not in patients with other forms of chronic
kidney disease (CKD) and the predominance of ‘ﬁngerprint’
A: T→T: A mutations in the p53 gene strongly support the
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authors’ conclusion that AA was the environmental mutagen
involved [10, 11]. AA nephropathy (AAN) and EN are very
similar in their clinical manifestations and pathophysiology
[13–15]. EN- and AA-related nephropathy have the same etiol-
ogy and depending on exposure dose and duration, one can
develop relatively rapid progressing renal disease as was the case
in the Belgian cohort, or a more slowly phenotype as was found
in EN [6, 10–15]. Observed differences between neighboring
villages in the prevalence of EN could reﬂect varying levels of
exposure based on differences in the microenvironment, agri-
cultural practices or dietary habits. In affected households, both
genetically related and non-related family members are at risk,
supporting the argument that household aggregation is more
important than heredity [16]. EN reﬂects interactions between
environmental factors and genes. EN patients could have the
same genetic variant, which if combined with the common
‘household’ exposure could result in disease. EN affects both
genders with slight female predominance.
Thus far, speciﬁc biomarkers for EN have not emerged
[1, 17, 18]. Diagnostic criteria for EN were described more
than 40 years ago but those currently used by EN centers
involve different combinations of elements, various cut-off
values and many of them are not in agreement with proposed
international guidelines [19–24]. Leaders of EN centers began
to address these problems at scientiﬁc meetings and this paper
is the outgrowth of those discussions.
Methodolical issues in epidemiology of EN
Position Statement 1: Early detection of EN/UUC is
important. Subjects who screen positive for EN should be
subjected to a diagnostic algorithm. Screening for EN is
not justiﬁed for children and teenagers, and screening out
of EN villages should be limited to sporadic forms of EN
and family members who moved from the endemic areas.
Ethical considerations should be taken into account in
screening surverys. Identiﬁcation of new EN foci is not a
priority.
Determination of kidney impairment in EN
The Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines recommend reporting estimated glomerular ﬁltration
rate (eGFR) in adults using the 2009 Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) creatinine equation
[24]. Serum creatinine should be measured using assays with
calibration traceable to the international standard reference
materials and minimally biased compared with isotope-dilution
mass spectrometry. Albumine-to-creatinine ratio (ACR) was
suggested for initial testing of proteinuria in untimed urine
samples [24]. ACR ≥30 mg/g should be conﬁrmed on a random
untimed urine with a subsequent early morning urine sample.
Postion Statement 2: eGFR and albuminuria (UAE) in
EN should be determined and interpreted as in all other
CKD patients according to the KDIGO 2012 recommen-
dations (24).
Proximal tubule dysfunction is a hallmark of EN. β2-micro-
globulin (β2M) has been used in screening of subjects for
EN [1, 17, 25], but certain disadvantages were realized.
Studies of cadmium nephropathy and EN suggested that
alpha1 microglobulin (α1M) is more reliable than β2M as a
biomarker of proximal tubule damage [17, 25]. In the
KDIGO 2012 guideline, α1M was the mostly discussed
protein in evaluation of tubular proteinuria [24]. Ikeda et al.
concluded that single determination of α1M is acceptable for
screening purposes, provided that samples have adequate
urine density [0.5< urine creatinine (g/L) <3.0; or 1.010<
speciﬁc gravity <1.030] [25]. A variety of cut-off values have
been used for α-1MCR. Based on the analysis of urine
samples of 939 subjects, values of 23.5 and 31.5 mg/g were
recently proposed as cut-off values for screening and con-
ﬁrming purposes, respectively [26]. Bergon et al. analyzed
the utility of α1M/UAE ratio and concluded that an α1M/
UAE ratio of 0.91 could be used as a discriminating value
[27]. Above this threshold, proteinuria could be deﬁned as
tubular in the presence of albuminuria. However, to avoid
possible bias caused with calculating ratios with small
numbers, it was proposed that in addition to α1M/UAE
>0.91, α1M should be above the cut-off value.
Position Statement 3: α1M is a reliable indicator of proxi-
mal tubular dysfunction in EN. A repeat sample should be
obtained from subjects with inadequate urine density. In
subjects with albuminuria, the ratio α1M/UAE might help
in distinguishing whether proteinuria is dominantly of
tubular origin.
Criteria for screening and conﬁrmation
UUC was for the ﬁrst time introduced as one of the criteria
for screening of EN. The other novelty in screening procedure
is recommendation for the screening for EN out of known
endemic villages. Based on observations and the fact that out
of established endemic villages farmers might have been
exposed to AA those who should be screened are listed in Pos-
ition Statement 5.
Position Statement 4. Criteria for screening in endemic vil-
lages are: Residency in known endemic village and/or in
households with cases of EN/UUC for more than 20 years;
proximal tubular damage; decreased eGFR; UUC.
Position Statement 5. Subjects who should undergo selec-
tive screening for EN out of endemic areas (‘sporadic EN’
cases) are: (i) Patients where there is no alternative expla-
nation for their CKD or patients with UUC living in
farming villages outside of endemic regions not restricted
only to Balkan region; (ii). Family members of: (a) patients
named in (i); (b) EN patients undergoing dialysis in non-
endemic dialysis units; (c) transplanted EN patients living
in non-endemic areas (emigrants).
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The diagnosis of EN can be conﬁrmed by pathologist.
However, it is not ethically justiﬁed or cost-effective to perform
renal biopsies on everyone suspected of contracting EN. As for
iatrogenic AA nephropathy, if no alternative cause of CKD is
identiﬁed, using elements listed in Position Statement 6, we
make a diagnosis of EN (Recommendation D).
Position Statement 6. Elements for establishing diagnosis
of EN:
1. Evidence that proximal tubular impairment is a
dominant feature.
2. Anemia adjusted to age and gender. Other causes of
anemia should be excluded.
3. Other kidney diseases should be excluded. Kidney
biopsy should be advised to patients where overlap-
ping with other CKD is suspected and to subjects
suspected of having ‘sporadic’ EN.
4. Environmental exposure to nephrotoxic agents other
than AA should be excluded.
Morphologic criteria of EN. There are no diagnostic fea-
tures which are pathognomonic of EN but the pattern of
injury, in the absence of other disease is highly suggestive of
this entity [28, 29].
Extensive hypocellular interstitial ﬁbrosis associated with
tubular atrophy involving medullary rays, the attending outer
medulla and the cortical labyrinth where it decreases typically
from the outer to the inner cortex is the consistent renal histo-
logic ﬁnding characterizing the chronic progressive nephropa-
thy affecting members of the same household in EN villages.
In approximately one-third of the cases, these changes are
accompanied by chronic interstitial inﬂammatory cells mainly
in medullary rays and/or outer medulla, usually less than that
might be expected in other renal diseases. About 40–46% of
the patients will develop multifocal urothelial cancer of the
transitional cell type usually in the upper urinary tract.
Glomerular and vascular lesions are associated with peri-
glomerular ﬁbrosis, glomerular lesions including ischemic, mi-
crocystic, obsolescent (collaptic type) glomeruli, occasional
thrombotic microangiopathy-like lesions (glomerular base-
ment membrane duplications or subendothelial ﬂuffy widen-
ing) and focal segmental sclerosis-like lesions. Vascular lesions
include arteriolar hyalinosis, intimal ﬁbrous hyperplasia,
occasional mucoid arterial intimal ﬁbrosis and by electron
microscopy multifocal thickening and splitting up of peritubu-
lar capillary basement membranes. These additional lesions
likely are secondary to the progressive kidney destruction by
the tubulointerstitial ﬁbrotic process. At end-stage, the kidneys
are extremely small, symmetrically contracted weighing only
20–30 g, each with smooth outlines. Histologic documentation
of incipient lesions in these patients are absent. All potential
causes of interstitial ﬁbrosing nephropathy must be ruled out
on the basis of morphologic and clinical data. This type of in-
terstitial ﬁbrosis is not seen in common end-stage renal failure
like nephrosclerosis, chronic pyelonephritis or reﬂux nephro-
pathy and chronic glomerulonephritis. In contrast, it shares re-
markable similarities with the type of renal ﬁbrosis found in
AAN which, in turn, is associated with a similar prevalence of
UUC as observed in EN. Nevertheless, a similar interstitial ﬁ-
brosis has been reported following exposure to cadmium, lead,
cyclosporin A, ifosfamide, pamidronate, lithium, nitrosoureas
and some herbal tea. Exposure to these agents should be ruled
out on the basis of clinical and anamnestic data. This list is not
exhaustive as other substances may induce a similar type of
renal ﬁbrosis. Of note, a similar pattern of renal ﬁbrosis has
been reported in pigs, but not in humans, exposed to OTA.
Although the pattern of renal interstitial ﬁbrosis in analges-
tic nephropathy is markedly different from AAN, it is associ-
ated with urothelial malignancy in 5–24% of patients. Thus,
consumption of non-steroidal antiinﬂammatory drugs
(NSAIDs) should be ruled out. Clinician, in conjunction with
the pathologist, should make a best diagnosis.
Diagnostic algorithm and guidelines for treatment
and follow-up (Figs 1 and 2)
Recommendation A: screening and monitoring
1A. The entire adult population of EN villages should be
screened. Diseased should be referred to local ne-
phrologists.
2A. Suspects and members of EN households with no
signs of either proximal tubular damage or UUC
should be monitored on a yearly basis.
3A. Mass screening procedure should be repeated in the
EN villages after ﬁve years.
4A. Tubular proteinuria, eGFR, red blood cell count,
and urine cytology should be determined.
5A. Renal function should be checked in all UUC
patients from farming villages. Renal cortex excised
during surgery (distant from tumor) should be ana-
lyzed for the evidence of EN, and if possible, should
be frozen at –20°C for subsequent determination of
the level of AA-DNA adducts. p53 mutational spec-
trum should be determined on tumor tissue.
6A. Patients with ESRD of unknown origin from non-
EN villages and members of such households
should be screened to identify cases of sporadic EN/
UUC.
Recommendations B-1: Diagnostic methods for EN.
1B. Only adequate random urine samples should be
utilized.
2B. Cut-off values for screening for UAE and α-1MCR
are 10 mg/L and 23.5 mg/g, respectively. α-lM/UAE
should be used to evaluate patients with albuminur-
ia. Cut-off value is ≥0.91. α-lMCR should be used
for conﬁrmation of diagnosis and for follow up.
Cut-off value is 31.5 mg/g .
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3B. 24-h protein excretion should be measured in sub-
jects with: reduced eGFR; with albuminuria and
α1M/UAE <0.91.
4B. GFR should be estimated using the 2009 CKD-EPI
equation.
5B. Patients with EN should be classiﬁed according to
the KDIGO 2012 Guideline.
6B. Anemia is deﬁned as a hemoglobin level <120 g/L
for men and women >50 years, and <110 g/L for
women ≤50 years.
7B. Renal biopsy should be considered in subjects with:
proteinuria ≥1.0 g/dU; with suspected other coexist-
ing kidney disease.
8B. Patients with EN in CKD stages ≥3A and patients
with histopathological ﬁndings associated with
chronic aristolochic acid nephropathy should be
monitored for UUC.
Recommendations B-2: Diagnostic methods for UUC
9B. Subjects at high risk for developing UUC (patients
with: histopathological ﬁndings indicative of EN; EN
patients in CKD stages ≥3A or undergoing dialysis)
should be monitored every 6 months using urine
cytology, ultrasound, and other imagine techniques.
10B. Members of EN households should be examined
every year.
11B. Patients with previous UUC, bladder cancer or having
hematuria should be examined every three months.
Hematuria should be evaluated by cystoscopy.
12B. Available imagine techniques (contrast CT and
ureteropyeloscopy) should be used to visualize
UUC [30].
13B. In EN transplant patients and in EN patients un-
dergoing dialysis cystoscopy should be performed
every 6 months.
F IGURE 1 : Diagnostic algorithm for endemic (Balkan) nephropathy. α-1M, alpha1 microglobulin (mg/L); UAC, albumin (mg/L); α-1MCR,
alpha1 microglobulin/urinary creatinine (mg/g), ACR, albumin to creatinine ratio. Orange arrow denotes optional; decision may be made by
nephrologist.
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Treatment and prevention of patients with EN
Recommendation C: Prevention and treatment
C1. Villagers should be informed that: (a) EN has insi-
dious onset but invariably progresses to ESRD and
that early diagnosis enables implementation of
treatment that may slow down the progression of
CKD; (b) EN and UUC are not hereditary diseases,
but also should know that genetic predisposition is
likely, but relevant only after long-term exposure to
environmental nephrotoxins.
C2. Villagers should be strongly encouraged to participate
in screening programs and to visit local nephrologists.
C3. Public health authorities should educate exposed
populations and the role of AA in EN should be
emphasized.
C4. Public health and agricultural authorities should
initiate efforts to eliminate Aristolochia from ﬁelds
where grain is harvested.
C5. Patients should be informed by family general prac-
titioners as to the importance of primary and secondary
prevention of CKD starting with the importance of life-
style changes, and about high risk of developing UUC
and the need for regular monitoring.
C6. Patients with established EN should be treated like
other patients with CKD and ESRD, by peritoneal
dialysis, hemodialysis or by renal transplantation.
Recommendation C: Treatment of patients with UUC
C10. Standard therapy is total nephroureterectomy with
excision of a cuff of bladder around ureteral ostium
and regional lymphadenectomy. This is supported
by the observation that recurrent tumors were ob-
served in EN patients more frequently than in other
patients with UUC.
As for iatrogenic form of aristolochic acid nephro-
pathy routine cystectomy is not recommended in
pre renal replacement therapy patients because the
incidence of bladder cancers was not found to be
F IGURE 2 : Diagnostic algorithm for patients with upper urothelial cancer and the risk for endemic (Balkan) nephropathy. For abbreviations,
see legend in Figure 1. Histopathology of renal cortex (distant from tumor) obtained during surgery of patient with UUC may be sufﬁcient for
making deﬁnitive diagnosis of EN. The proposed algorithm will help to establish the degree of renal impairment, and it is also recommended for
patients with bladder cancer. If the diagnosis of EN is established, further examination of upper urinary tract is warranted. As hematuria is fre-
quently present in patients with urothelial cancer, dipstick is unreliable.
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higher than of UUC. Cystectomy should be advised
if AA-DNA adducts are detected in bladder tissue.
C11. A conservative surgical approach should be reserved
only for the highly selected patients with bilateral
tumors in whom nephron sparing is essential.
Patients treated with a conservative approach are at
increased risk of local recurrence and require fre-
quent and careful follow-up including imaging pro-
cedures and endoscopies.
C12. All patients with UUC should be monitored care-
fully for recurrent or new tumors.
C13. Systemic chemotherapy for unresectable and meta-
static disease is indicated and all other oncologic
treatment and monitoring of EN/UUC patients
should follow general recommendations [30].
Renal transplantation in EN
In recent years, the number of renal-transplanted patients
in Croatia has signiﬁcantly increased. It is hoped that a
similar pattern will follow in other countries harboring EN.
Transplanted AAN patients are at high risk of developing
UUC [31]. For this reason, AAN patients underwent bilat-
eral nephroureterectomy either before or after renal trans-
plantation. In Croatian registry, in the group of 40
transplanted EN patients more than 40% developed UUC
[32]. This fact argues strongly for bilateral nephrectomy of
native kidneys in EN-transplanted patients. The level of AA–
DNA adducts should be determined in renal cortical tissue of
removed kidneys [10, 11]. It was proposed that an inter-
national registry should be established for renal transplant
recipients with EN. No recurrence of EN has been found after
transplantation.
Recommendation C: Renal transplantation for patients
with EN
C15. EN patients should be placed on waiting lists for
renal transplantation along with other patients
with ESRD but should undergo appropriate exam-
inations before to exclude urothelial cancers.
C16. For living donor transplantation, additional inves-
tigations should be performed. If the donor lived
in the EN region for more than 15 years, renal
biopsy should be performed to exclude EN and/or
presence of AA–DNA adducts. Finding of each of
them would exclude the subject as a living donor.
C17. Considering the reported high incidence of UUC
in EN/AAN transplanted patients, all patients with
EN should undergo bilateral nephroureterectomy
before transplantation. Bilateral nephroureterectomy
should be performed in all EN recipients younger
than 65 years. In EN patients older than 65 years
bilateral nephroureterectomy should be performed
prior to renal transplantation if (a) UUC or bladder
cancer were already diagnosed; (b) family history for
UUC or EN is positive
C18. After transplantation, EN patients who refused bilat-
eral nephroureterctomy should be monitored closely
for UUC.
C19. Immunosuppression with mTOR inhibitors should
be considered for EN-transplanted patients.
Recommendation D: Classiﬁcation of EN
I. Diseased/affected II. Suspected EN
(1) Biopsy proven/indicative of EN1
or
(2) Residency in an EN household >20 years
+ tubular proteinuria2
+ decreased eGFR
+ anemia2
or
(3) Residency in EN village >20 years
+ UUC
+ tubular proteinuria2
(1) Residency in EN household >20 years
+ reduced eGFR
+ anemia3
or
(2) Residency in EN household >20 years
+ tubular proteinuria2
or
(3) Residency in EN village >20 years
+ UUC
III. High risk group for EN IV. Sporadic EN4
(1) Residency in EN households >20 years
(2) Residency in households with sporadic/
suspected EN cases >20 years
Biopsy proven/indicative of EN in patient with UUC outside of the
endemic region or in member of their household
1There are no diagnostic features which are pathognomonic of EN but the pattern of injury, in the absence of other disease is highly
suggestive of this entity. Detection of AA–DNA adducts and p53 ﬁngerprint mutation is diagnostic.
2α-1MCR >31.5 mg/g and α-1/UAC ≥0.91.
3Hemoglobin <120 g/L for men and women >50 years, and <110 g/L for women ≥50 years.
4Subjects with chronic interstitial nephropathies where other causes should be excluded (reﬂux nephropathy, chronic pyelonehritis,
recurrent pyelonephritis, hypertensive nephrosclerosis, exposure to lead, cadmium, herbs containing AA, cyclosporin A, ifosfamide,
pamidronate, lithium and nitrosoureas, heavy use of NSAID).
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Classiﬁcation of EN population
Population of EN villages should be classiﬁed as described.
Patients with UUC living in non-EN villages and members of
their households should be screened for sporadic EN. In EN
patients and in those suspected of having EN, other causes of
chronic tubulointerstitial nephropathies should be excluded as
well as occupational exposure to nephrotoxic agents and the
ingestion of herbs. The latter must be repeatedly asked to the
patients as most of them do not even mention their consump-
tion as they believe that herbal remedies are natural hence in-
nocuous products.
Concluding statement
EN is a form of chronic AA nephropathy where environ-
mental etiological agent, i.e. AA, was ingested over years in
small doses via contaminated bread contrary to AA nephropa-
thy described worldwide where the same agent was ingested in
higher doses either intentionally or inadvertently as a part of a
medical treatment. Renal community all over the world should
become aware that Balkan endemic nephropathy and AA nephro-
pathy are the same disease frequently associated with upper ur-
othelial cancers and caused with the same toxin. Balkan endemic
nephropathy and AA nephropathy differ only in the clinical
course.
This document should be adopted by responsible insti-
tutions in countries harboring EN. National medical providers
(state health insurance companies) should cover costs of screen-
ing and diagnostic procedures and treatment of EN patients
with or without UUC. Diagnostic algorithm and guidelines
should be updated when new evidence-based data is in hand.
DISCLAIMER
This consensus document represents views of the international
workgroup of experts in endemic nephroapthy and AA ne-
phropathy and this position statement is not an ofﬁcial view of
ERA-EDTA.
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